Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept.

Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, Thiesen HJ (2008) Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res Ther 10(3), R50. PubMed

Abstract

About 30% of rheumatoid arthritis patients fail to respond adequately to TNFalpha-blocking therapy. There is a medical and socioeconomic need to identify molecular markers for an early prediction of responders and nonresponders.

Beteiligte Abteilungen und Gruppen
HKI-Autoren
Themenfelder
Identifier

doi: 10.1186/ar2419 PMID: 18454843